Clinical trials: Autoinflammatory Syndrome
Behcet's Disease
The Role of Rosuvastatin on Vascular Involvement in Behçet's Disease
Behçet's Disease(BD) is a systemic inflammatory vasculitis, which affects all types and sizes of vessels. Statins display numerous effects often independent of the well-established lipid-lowering effects that may be of benefit in…
- Trial name
- NCT04328064
- Testing
- Rosuvastatin calcium 40mg
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of Alexandria
Cryopyrin Associated Periodic Syndrome, Familial Cold Urticaria
Circadian Rhythm Deregulation in Patients With CAPS
Circadian rhythms are characterized by the physiology's adaptation to the alternation of day and night, enabling to adapt to the environment. These rhythms are generated by a molecular clock within each cell.
- Conditions
- Cryopyrin Associated Periodic Syndrome, Familial Cold Urticaria, Muckle-Wells Syndrome, CINCA Syndrome
- Trial name
- ICARUS (NCT06544018)
- Testing
- Genetic analysis of NLRP3, Circadian rhythm measurement, Saliva sampling
- Where
- 6 sites in France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome
Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
To date there are no approved effective therapies for the treatment of cryopyrin-associated periodic syndromes (CAPS) including Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), or Neonatal Onset…
- Conditions
- Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
- Trial name
- NCT00991146
- Testing
- canakinumab
- Where
- 3 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Ocular Behcet's Disease,, Non-Infectious Uveitis
Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease
Objectives: To describe the safety and efficacy of intravitreal flucinolone acetonide implants in the management of patients having refractory ocular Behcet's disease Hypothesis: A descriptive observational study Study design: A…
- Conditions
- Ocular Behcet's Disease,, Non-Infectious Uveitis, Refractory Uveitis
- Trial name
- NCT00720928
- Testing
- flucinolone acetonide
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Asan Medical Center
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
This is a long-term extension trial of RAY121 in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing…
- Conditions
- Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
- Trial name
- NCT06723106
- Testing
- RAY121
- Where
- 62 sites in Australia, Austria and 17 more
- Volunteers
- 144 people
- Sponsor
- Chugai Pharmaceutical
Schnitzler Syndrome
Ilaris® Effects in Schnitzler Syndrome (ILESCH)
This is a multi-center double-blind placebo-controlled study to assess the efficacy and safety of canakinumab (trade name Ilaris®), a high-affinity monoclonal antibody that neutralizes IL-1β, in patients with Schnitzler syndrome.
- Trial name
- ILESCH (NCT01390350)
- Testing
- Canakinumab
- Where
- 5 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Charite University, Berlin, Germany
Behçet's Disease, Psychiatric Disorders
Psychiatric Manifestations Associated With Behcet's Disease
The psychoBehçet'study is aimed at evaluating the psychological and neurocognitive symptoms in 25 consecutive patients followed for Behçet's disease. This is a monocentric, observational, non interventional study.
- Trial name
- PSYCHO-B7 (NCT04585360)
- Testing
- Questionnaires evaluating anxiety and depression symptoms, tiredness, and quality of life
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
This study is a Phase 2 trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in patients with NLRC4-GOF, XIAP deficiency, or CDC42 mutations.
- Trial name
- MASter-1 (NCT04641442)
- Testing
- MAS825
- Where
- 12 sites in United States, Czechia and 5 more
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals
Behcet Disease
A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease
The purpose of this study is to evaluate the efficacy of infliximab in induction regimen by assessing the mean decrease in Disease Activity Index for intestinal Behcet's disease (DAIBD) score of 20 or more in participants with…
- Trial name
- BEGIN (NCT02505568)
- Testing
- Infliximab
- Where
- 5 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Janssen Korea, Ltd., Korea
Behcet Syndrome
Upadacitinib for Refractory Behcet's Syndrome
Behçet's syndrome (BS) is a systemic autoimmune vasculitis that can affect multiple organs, including the skin, eyes, and vascular system.
- Trial name
- NCT07080346
- Testing
- Upadacitinib 15 MG
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Liu Tian
Behcet Disease and Vascular Affection
Serum Elafin and Vascular Affection in Behcet Disease
To measure the level of serum elafin in patients with BD. To assess the relation between serum elafin levels and disease activity.
- Trial name
- NCT06272929
- Testing
- doppler ultrasound
- Volunteers
- 90 people
- Sponsor
- Assiut University
Behcet Syndrome
Zinc Supplementation and Behçet's Syndrome
To study the effects of zinc gluconate supplementation on patients with Behçet's syndrome, 50 patients will be randomly allocated to two groups: placebo group or zinc group (one tablet of 30 mg/day elemental zinc) for 12 weeks.
- Trial name
- NCT05098678
- Testing
- Zinc gluconate
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- Tabriz University of Medical Sciences
Hereditary Autoinflammatory Diseases, Schnitzler Syndrome
AutoInflammatory Disease Alliance Registry (AIDA)
Autoinflammatory diseases (AID) are clinical entities characterized by recurrent inflammatory attacks in absence of infection, neoplasm or deregulation of the adaptive immune system.
- Conditions
- Hereditary Autoinflammatory Diseases, Schnitzler Syndrome, Behcet Syndrome, PFAPA Syndrome
- Trial name
- AIDA (NCT05200715)
- Testing
- No intervention is foreseen by the protocol.
- Where
- 112 sites in Algeria, Australia and 20 more
- Volunteers
- 3,500 people
- Sponsor
- University of Siena
Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Inflammatory symptoms of Cryopyrin-Associated Periodic Syndrome (CAPS) are due to mutations in a the NLRP-3 gene (previously known as Cold Induced Autoinflammatory Syndrome-1 or CIAS1).
- Conditions
- Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS), Genetic Diseases, Inborn
- Trial name
- NCT00288704
- Testing
- rilonacept 160 mg
- Where
- 24 sites in United States
- Volunteers
- 104 people
- Sponsor
- Regeneron Pharmaceuticals
Inflammation, Familial Mediterranean Fever
Interleukin-1 Trap to Treat Autoinflammatory Diseases
Autoinflammatory diseases are illnesses characterized by episodes of inflammation that, unlike autoimmune disorders, lack the production of high titer autoantibodies or antigen-specific T cells.
- Conditions
- Inflammation, Familial Mediterranean Fever, Still's Disease, Adult-Onset
- Trial name
- NCT00094900
- Testing
- IL-1 Trap
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Fibromyalgia, Behcet Syndrome
Frequency of Fibromyalgia in Behcet Disease
In various studies, the incidence of fibromyalgia in Behçet's patients is widely distributed. It was aimed to investigate the frequency and severity of fibromyalgia in Behcet disease in province Bursa.
- Trial name
- NCT03514056
- Testing
- group 1:Patients diagnosed with Behcet disease, group 2: Patient diagnosed with fibromyalgia without Behcet disease
- Where
- Turkey (Türkiye)
- Volunteers
- 146 people
- Sponsor
- Bursa Yuksek Ihtisas Training and Research Hospital
Behçet Disease, Behcet's Disease Aggravated
Behçet's Disease Overall Damage Index
Damage in vasculitis, as well as in other chronic inflammatory disorders, accrues over time resulting in impairment of quality of life, development of disability and increased mortality.
- Trial name
- BODI (NCT03803462)
- Testing
- Behçet's disease Overall Damage Index (BODI)
- Where
- 10 sites in Greece, Italy and 3 more
- Volunteers
- 210 people
- Sponsor
- University of Cagliari
Muckle-Wells Syndrome, Schnitzler Syndrome
Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)
This is a single-center open label study of the IL-1 transfusion protein rilonacept in subjects with Muckle-Wells syndrome (MWS), or Schnitzler syndrome (SchS) in Germany.
- Trial name
- ACCILTRA1 (NCT01045772)
- Testing
- rilonacept
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Charite University, Berlin, Germany
Behcet Syndrome
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease
The purpose of this study is to assess whether Apremilast is safe and effective in the treatment of patients with Behcet Disease.
- Trial name
- NCT00866359
- Testing
- Apremilast (CC-10004)
- Where
- 7 sites in United States, Turkey (Türkiye)
- Volunteers
- 111 people
- Sponsor
- Amgen
Behçet Disease
Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease
The purpose of this study is to evaluate the proof of concept of efficacy of ustekinumab in subjects with Behçet disease, including patients with oral ulcers (STELABEC-1) and patients with active posterior uveitis or panuveitis…
- Trial name
- STELABEC (NCT02648581)
- Testing
- Subcutaneous Ustekinumab
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris